Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy

Pötter, Richard; Limbergen, Erik; Gerstner, Natascha; Wambersie, André

doi:10.1016/s0167-8140(00)00266-8

Cited by 78 publications

(30 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the bladder, the overall situation for dose volume assessment applying 3D based parameter (2 ccm, 0.1 ccm) presents still with little clinical evidence. This is in line with the difficulty of showing dose effects for cervix cancer BT for the bladder in the past [42]. For centres changing from radiography to 3D based dose volume assessment it has been striking that in the past high doses have been applied in small volumes on a regular basis, often far beyond what has been shown by the ICRU bladder point.…”

Section: Dose Response Relationship For Local Controlmentioning

confidence: 83%

See 1 more Smart Citation

Present status and future of high-precision image guided adaptive brachytherapy for cervix carcinoma

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Dose Response Relationship For Local Controlmentioning

confidence: 83%

“…As there were no evidence based limits for the sigmoid, the rectum constraints were applied. For the bladder the available literature data on dose effects were not straightforward [40,42]. Dose constraints were determined based on the current and traditional clinical practice.…”

Section: Dose Response Relationship For Local Controlmentioning

confidence: 99%

Present status and future of high-precision image guided adaptive brachytherapy for cervix carcinoma

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…90,91 For instance, a statistical discrepancy criterion could be defined in order to monitor the dose at reporting points. However, dose estimates at ICRU reporting points have been shown to be unreliable given practical difficulties to position the dosemeter probe accurately in the steep dose gradient regions.…”

Section: This Error Detection Technique Was Proposed By Sheikh-baghermentioning

confidence: 99%

In vivodosimetry: trends and prospects for brachytherapy

Kertzscher¹,

Rosenfeld²,

Beddar³

et al. 2014

BJR

View full text Add to dashboard Cite

The error types during brachytherapy (BT) treatments and their occurrence rates are not well known. The limited knowledge is partly attributed to the lack of independent verification systems of the treatment progression in the clinical workflow routine. Within the field of in vivo dosimetry (IVD), it is established that real-time IVD can provide efficient error detection and treatment verification. However, it is also recognized that widespread implementations are hampered by the lack of available high-accuracy IVD systems that are straightforward for the clinical staff to use. This article highlights the capabilities of the state-of-the-art IVD technology in the context of error detection and quality assurance (QA) and discusses related prospects of the latest developments within the field. The article emphasizes the main challenges responsible for the limited practice of IVD and provides descriptions on how they can be overcome. Finally, the article suggests a framework for collaborations between BT clinics that implemented IVD on a routine basis and postulates that such collaborations could improve BT QA measures and the knowledge about BT error types and their occurrence rates.

show abstract

“…Although ICRU Report 38 recommended reporting of the 60 Gy reference isodose dimensions and other parameters including the ICRU reference volumes and doses to OARs, a survey by Pötter et al [23] showed that these guidelines are usually not followed, nor are they reported by most centres in clinical practice or in the literature related to HDR ICBT. The variations in the ICRU Report 38 reference volumes with multiple HDR applications could have further added complexity to the reporting parameters and therefore might not have been favoured by 767 October 10, 2014|Volume 5|Issue 4| WJCO|www.wjgnet.com [18] .…”

Section: A Need Towards Image Guided Brachytherapy: Ct Based Intracavmentioning

confidence: 99%

Brachytherapy in cancer cervix: Time to move ahead from point A?

Srivastava¹

2014

WJCO

View full text Add to dashboard Cite

Brachytherapy forms an integral part of the radiation therapy in cancer cervix. The dose prescription for intracavitary brachytherapy (ICBT) in cancer cervix is based on Tod and Meredith's point A and has been in practice since 1938. This was proposed at a time when accessibility to imaging technology and dose computation facilities was limited. The concept has been in practice worldwide for more than half a century and has been the fulcrum of all ICBT treatments, strategies and outcome measures. The method is simple and can be adapted by all centres practicing ICBT in cancer cervix. However, with the widespread availability of imaging techniques, clinical use of different dose-rates, availability of a host of applicators fabricated with image compatible materials, radiobiological implications of dose equivalence and its impact on tumour and organs at risk; more and more weight is being laid down on individualised image based brachytherapy. Thus, computed tomography, magnetic-resonance imaging and even positron emission computerized tomography along with brachytherapy treatment planning system are being increasingly adopted with promising outcomes. The present article reviews the evolution of dose prescription concepts in ICBT in cancer cervix and brings forward the need for image based brachytherapy to evaluate clinical outcomes. As is evident, a gradual transition from "point" based brachytherapy to "profile" based image guided brachytherapy is gaining widespread acceptance for dose prescription, reporting and outcome evaluation in the clinical practice of ICBT in cancer cervix.

show abstract

Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy

Cited by 78 publications

References 22 publications

Present status and future of high-precision image guided adaptive brachytherapy for cervix carcinoma

Present status and future of high-precision image guided adaptive brachytherapy for cervix carcinoma

In vivodosimetry: trends and prospects for brachytherapy

Brachytherapy in cancer cervix: Time to move ahead from point A?

Contact Info

Product

Resources

About